Price Action, DOJ Probe Overhang, and the Latest Forecasts on Dec. 24, 2025
Dec. 24, 2025 — Regencell Bioscience Holdings Limited (Nasdaq: RGC) is once again reminding markets that “biotech stock” plus “low float” can equal “physics optional.” By the close of trading on December 24, RGC finished at $24.60, down 2.57% from the prior close of $25.25, after trading between $24.60 and $26.42 on the day, with roughly 348K shares traded. [1]
That’s the headline tape. The deeper story—what’s making RGC such a recurring character in 2025’s “stock market does weird things” anthology—mixes extreme volatility, concentrated insider ownership, a past 38-for-1 stock split, and a disclosed U.S. Department of Justice (DOJ) inquiry into trading activity in the company’s shares. [2]
Below is a full…
